There's growing evidence to suggest that GLP-1 drugs, which include Ozempic's semaglutide, may be useful for treating alcohol ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

On Today with Claire Byrne, Maura Fay reports on the rollout of Mounjaro in Ireland and speaks to medical experts about issues surrounding access to this medication. Listen back above. The most ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

With weight loss drugs such as Ozempic and Mounjaro seemingly able to melt the pounds away, you might well think you'll never need a 'diet plan' again. Alas, you'd be wrong. As a leading weight ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly (NYSE:LLY) reported strong Q4 2024 results on Thursday, surpassing Wall Street estimates, driven by a more than twofold increase in sales of its weight loss and diabetes drugs Mounjaro ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...